All In Biotech

NDA 209376 · Am Regent

Multrys

Cupric Sulfate, Manganese Sulfate, Selenious Acid, Zinc Sulfate · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 2, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

14

10 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2024.

Multrys is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Multrys is a combination of trace elements (zinc sulfate, cupric sulfate, manganese sulfate, and selenious acid) indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Zinc Zinc functions as a cofactor of various enzymes including DNA polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of substrates of carbonic anhydrase in erythrocyte. Copper Copper is a cofactor for many metalloenzymes acting as an oxidase to achieve reduction of molecular oxygen. Examples of copper metalloenzymes include but are not limited to lysyl...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • MULTRYS · CUPRIC SULFATE EQ 60MCG COPPER/ML; MANGANESE SULFATE EQ 3MCG BASE/ML; SELENIOUS ACID EQ 6MCG SELENIUM/ML; ZINC SULFATE EQ 1000MCG BASE/ML (1ML) · SOLUTION, INTRAVENOUS · Prescription
  • TRALEMENT · CUPRIC SULFATE EQ 0.3MG COPPER/ML; MANGANESE SULFATE EQ 55MCG BASE/ML; SELENIOUS ACID EQ 60MCG SELENIUM/ML; ZINC SULFATE EQ 3MG BASE/ML (1ML) · SOLUTION, INTRAVENOUS · Prescription
  • TRALEMENT · CUPRIC SULFATE EQ 0.3MG COPPER/ML; MANGANESE SULFATE EQ 55MCG BASE/ML; SELENIOUS ACID EQ 60MCG SELENIUM/ML; ZINC SULFATE EQ 3MG BASE/ML (5ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cupric" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia4
  • product label confusion3
  • anaemia2
  • diarrhoea2
  • fall2
  • hospitalisation2
  • infection2
  • muscular weakness2
  • pain2
  • physical product label issue2
  • product dose omission issue2
  • vomiting2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20213
20222
20231
20241
20267

Recalls

2 FDA enforcement reports for this application.

  • Jul 24, 2026 · Class II · Ongoing

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

  • Jul 24, 2026 · Class II · Ongoing

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Am Regent · Also marketed as Tralement

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.